The approval of the twice-daily pill remibrutinib positions the company to challenge injectable treatments in a multi-billion dollar market.
Late-breaking trial results for obefazimod show significant efficacy, positioning the first-in-class oral therapy in a competitive market.
Shares fall despite strong Q3 sales, as expiring EV tax credits and valuation concerns spook investors.
The utility giant reaffirmed its adjusted EPS targets for 2025 and 2026, reinforcing a long-term earnings growth strategy of 7% to 9% through 2029.
Combination therapy approval for small cell lung cancer offers a new standard of care and a bullish signal for the pharmaceutical sector.
A coalition of influential investors is urging shareholders to reject the CEO's new compensation package, citing major governance concerns.
First-of-its-kind maintenance therapy approved for extensive-stage small cell lung cancer, a historically difficult-to-treat malignancy.
H.C. Wainwright more than doubles its price target to $7 as the company delivers its first electrolyzer to a major green hydrogen facility in Portugal.